Loading
An adenovirus missing the gene that disables the cell's main tumour suppressor appeared to grow only in cancer cells that had already lost that suppressor, a claim that launched the field's first big clinical programme and was later shown to be the wrong explanation.
Adenovirus E1B encodes a 55-kilodalton protein that inactivates p53. Bischoff and colleagues showed that a mutant adenovirus lacking it replicated in and lysed p53-deficient human tumour cells but not cells with functional p53, and that putting the 55-kilodalton protein back into the latter made them susceptible. Injection into p53-deficient human cervical carcinomas in nude mice significantly reduced tumour size and completely regressed 60 per cent of tumours.
The virus became ONYX-015, the most heavily studied oncolytic virus of the 1990s, and later, with a nearly identical design, the Chinese product H101. The tidy mechanism did not survive: O'Shea and colleagues showed in 2004 that selectivity tracks late viral RNA export rather than p53 status, which is why ONYX-015 activity in trials never sorted by p53.
This is the paper that made oncolytic viruses look like precision medicine: a named genetic lesion, a virus built to exploit it, a biomarker to select patients. None of that held. It is the field's most useful cautionary tale, because the drug went into large trials on a mechanism that turned out to be wrong, and the selectivity that does exist has never been reducible to one gene.
Shares Science, Oncolytic viruses.
Shares Science, Oncolytic viruses.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/